Buy the full study
Summary
The global aesthetic medicine market, valued at $52.5 billion, has been exhibiting robust growth, with expectations to expand at a CAGR of 8.9% . Technological advancements, particularly in non-invasive body contouring systems, are spurring increased demand for aesthetic treatments. Despite the impact of the COVID-19 pandemic in early 2020, which led to clinic closures and reduced service interest, the sector rebounded with significant post-lockdown demand surges, with practitioners reporting a 33.67% increase in clientele.
The shift to telemedicine became more pronounced during this period, with a 70% uptick in remote consultations. Furthermore, the "Zoom Effect," stemming from heightened use of video conferencing platforms, catalyzed a rise in demand for facial and neck/jaw rejuvenation procedures. The UK market mirrored these trends, seeing its non-surgical cosmetic medicine market grow to £3.6 billion. Regulation of the industry remains limited, although the UK introduced licensing measures for non-surgical procedures to enhance patient safety.
The onset of the COVID-19 pandemic significantly impacted the sector, with over 80% of clinics reportedly shutting down, approximately two-thirds experiencing revenue dips, and a noticeable decline in service interest by more than 60%. Despite these initial setbacks, the sector rebounded as restrictions eased, with more than one-third of practitioners observing an uptick in their client base.
One peculiar phenomenon affecting demand in the UK's aesthetic medicine market has been dubbed the "Zoom Effect." As video conferencing became the norm for both professional and personal communication due to lockdowns, individuals found themselves confronting their visage more frequently on screens. The heightened awareness of facial appearance brought forth by these virtual platforms has driven a preference for non-invasive facial procedures that target perceived imperfections, with particular attention to the neck and jawline areas.
Key Players in the Aesthetic Medicine Industry
The aesthetic medicine industry features a dynamic range of companies, each specializing in distinctive segments and contributing significantly to the field's progress. Among the major players, Allergan plc and Ipsen stand out prominently in the manufacturing of injectable products, while companies like Cynosure and Alma Lasers exert their strength in the production of specialized aesthetic equipment. Here's a closer look at these influential entities reshaping the way aesthetic treatments are administered.
Allergan plc : Allergan plc is a name synonymous with the aesthetic medicine industry. Known for its global presence and extensive portfolio, the company is a titan in the field of injectable products. With a rich legacy of innovation, Allergan has been instrumental in developing and marketing a range of botulinum toxin products, notably Botox, which has become almost a household name in the realm of non-invasive cosmetic procedures. Allergan’s commitment to research and development continues to drive the industry forward, making it a trusted brand for patients and practitioners alike.
Ipsen Another significant player in the injectables segment of the aesthetic medicine market is Ipsen. This global biopharmaceutical group focuses on transformative treatments in Oncology, Neuroscience, and Rare Diseases, while also providing effective solutions in aesthetic medicine. Ipsen's commitment to improving patient care is evident in its strategic development of innovative therapeutics that meet the evolving needs of the medical community and their patients.
Merz Pharmaceuticals : Merz Pharmaceuticals is a company held in high regard for its contributions to the development of injectable products. With a keen focus on patient-centric solutions, Merz has developed a range of products that cater to the growing demand for minimally invasive aesthetic treatments, building a strong reputation for quality and safety in the industry. #### Cynosure Venturing into the equipment segment, Cynosure stands out as a key manufacturer of high-end aesthetic devices. The company's prowess lies in its broad array of energy-based equipment designed for a multitude of treatments, including hair removal, fat reduction, and skin resurfacing. Cynosure's commitment to technological advancement ensures that practitioners are equipped with cutting-edge tools to deliver state-of-the-art aesthetic services.
Alma Lasers : Alma Lasers is another esteemed entity in the production of aesthetic medical equipment. Renowned for its innovative laser, light-based, radiofrequency, and ultrasound solutions, Alma Lasers delivers a suite of products that address a wide range of cosmetic concerns. The company's dedication to clinical excellence
to understand this market
Detailed content
Inforamtion
- Number of pages : 30 pages
- Format : Digital and PDF versions
- Last update : 08/04/2022
Summary and extracts
1 Market overview
1.1 Definition and presentation
Aesthetic medicine works to change the physical appearance of the patient. Unlike traditional surgery, cosmetic medicine treatments are quick, simple, less expensive and not permanent, which reduces the risks. Cosmetic medicine can be divided into two procedures:
- Invasive (or "surgical"): Breast augmentation, liposuction, tummy tuck, nose reshaping...
- Non-invasive ( or non-surgical): Botox injections, laser hair removal, chemical peels, fillers...
The UK clinical market is highly fragmented with several key players including Cynosure Inc, Alma Lasers, Lumenis Inc, Syneron Medical Ltd and Sciton Ltd
Demand is expected to increase; by 2020, an estimated 1.5 million people in the UK will have undergone non-surgical treatment[Generation]. This development is partly attributed to the role of social networks in encouraging greater acceptance of cosmetic treatments. In addition, technological advances have driven down prices and allow for minimal surgical procedures. As a result, 66% of young British people would have liked to change the structure of their face, according to a survey by Save Face.
Nevertheless, the industry is subject to several challenges; regulation remains weak, raising concerns about the quality and accountability of small-scale surgeons. According to a survey by Cosmetic surgery solicitors, 83% of women aged 18 to 30 were in favor of having a body part altered if the health risks were not considered
1.2 A rapidly growing global market
The global aesthetic medicine market was valued at $**.* billion in **** and is expected to grow at a CAGR of *.*% by ****. Innovation in aesthetic devices over the past decade has led to growth in demand for aesthetic treatments.
The introduction of technically advanced products, such as non-invasive body contouring systems using controlled ...
1.3 The UK market
In ****, the UK cosmetic surgery market was worth £*.* billion, with * out of ** procedures being non-invasive, while the market for cosmetic medicine was £*.** billion which accounts for **% of the cosmetic surgery market. [***]
By ****, the non-surgical cosmetic medicine market had grown to £*.* billion. [***]
UK cosmetic medicine market United Kingdom, ****-****, £ billion Source: ****
2 Analysis of the demand
2.1 Popular beauty treatments in the UK
The following charts detail the most popular types of cosmetic medicine treatments in the United Kingdom. For example, age-related treatments represent the largest share of aesthetic medicine.
Popular Aesthetic Medicine Treatments in the UK United Kingdom, ****, in percent Source: ****
Looking specifically at the types of treatments offered, botulinum toxin and dermal ...
2.2 Management of complications
In ****, figures from insurer Hamilton Fraser report that **% of cosmetic medicine treatments had not resulted in complications. However, **% of treatments had induced the need for further intervention by a medical professional. During this period, **% of complications were due to swelling.
However, in ****, the British College of Aesthetic Medicine reported *** complications with ...
2.3 Demand trends
Increased post-lockdown demand
The first quarter of **** heralded complications for the sector related to the health crisis. Eighty-one percent of clinics had been forced to close, **% had experienced a decrease in revenue, and **% noted lower interest in their services.
The later stages of the crisis, however, were marked by an increase ...
3 Market structure
3.1 A market structured around equipment manufacturers and practitioners
The aesthetic medicine value chain consists of several steps. First, raw materials are supplied to equipment manufacturers, who process them to produce the medical equipment. The latter is then purchased by medical institutions, hospitals and aesthetic medicine centers and is finally used to perform a non-surgical procedure on the final ...
3.2 Production of aesthetic medicine equipment
The production of equipment for aesthetic purposes includes the manufacture of breast prostheses, injectables, equipment and finally cosmeceuticals. As the aesthetic market requires high entry costs and advanced technology, most manufacturers are in the production of one of these segments.
As the main players in the market are international groups, most ...
4 Analysis of the offer
4.1 Overview of the offer
The offer on the aesthetic medicine market can be segmented as follows
*. Injectables
Botulinum toxin: Botulinum toxin acts by inhibiting the release of the neurotransmitter acetylcholine: by blocking its release in the muscles, it reduces excessive facial mimicry and thus blocks the sagging of the skin, the primary cause of ...
4.2 Price summary
The following table summarizes the characteristics of non-surgical cosmetic procedures available on the UK market:
Source: ****
It is important to note that prices vary considerably depending on the medical facility, doctor or region.
5 Regulation
5.1 Limited UK regulation
In the United Kingdom, training is not required for the right to administer non-surgical cosmetic treatments. Thus, anyone can now legally administer botulinum toxin. However, we have seen that these procedures often lead to complications. Organizations such as Save Face are dedicated to helping potential treatment recipients find sufficiently experienced ...
6 Positioning of the actors
6.1 Segmentation
- Allergan plc
- Ipsen
- Merz Pharmaceuticals
- Cynosure
- Alma Lasers
List of charts
- The global aesthetic medicine market by value
- Popular Cosmetic Medicine Treatments in the UK
- Popular types of treatment in the UK
- Treatments with complications
- Who did you turn to for advice in the event of a complication?
All our studies are available online in PDF format
Take a look at an example of our research on another market!
Latest news
Ipsen's commitment to the area of rare diseases - 29/02/2024
Performance and strategies of the biopharmaceutical company Ipsen in 2023: 1. **Increase in sales:** In 2023, Ipsen recorded an increase in global sales of 3.4% over the previous year. 2. **Operating margin:** The company recorded an operating margin of 26.1%, which shows an increase of 2% compared to 2022. 3. **Growth factors:** Growth was supported by the company's historical assets, new drugs, pipeline expansion, and accelerated investment in research and development, particularly benefited by recent acquisitions focused on the area of rare diseases. 4. **Entry into the rare disease area:** In 2023, Ipsen acquired Albireo, a leading developer of bile acid modulators for the treatment of pediatric and adult cholestatic liver disease, bringing odevixibat, the first approved treatment against progressive familial intrahepatic cholestasis (Pfic), to the market. 5. **Future Plans:** By 2024, Ipsen plans to launch four innovative therapies worldwide and expand its pipeline, supported by an external innovation strategy in its three core therapeutic areas. 6. **Rare disease commitment:** With new developments such as odevixibat and an evolving pipeline, Ipsen marks its official entry into the rare disease field, aiming to bring therapeutic innovations that can change the course of disease, with a focus on drugs with novel mechanisms of action.
Botox: botulinum toxin boosts pharma's bottom line - 02/08/2023
- The United States accounts for half of the global botulinum toxin market.
- Last year, Botox accounted for $5.2 billion in worldwide sales for AbbVie, with equal shares between aesthetics (+21% excluding currency effect) and therapeutics (+13%).
- In the United States, Dysport (Ipsen) has only 5% of the therapeutic market, compared with 30% in France.
- In aesthetics in the US, Ipsen has an estimated share of between 20% and 25%.
- Of the French laboratory Ipsen's half-year sales of 1.5 billion euros (+7%), 319 million (+32%) come from botulinum toxin sold in therapeutics and, in some countries, in aesthetics.
- Botox holds 40% to 50% of the therapeutic market in France, compared with 30% for Ipsen.
Medicine, Allergan Aesthetics launches training center for healthcare professionals - 26/06/2023
Inauguration of Allergan Aesthetics' Center of Excellence in Italy, specifically in Rome. This center represents the first and only space completely dedicated to both theoretical and practical training of healthcare professionals. Its foundation is supported by the expertise of a multidisciplinary scientific committee composed of 21 nationally and internationally renowned experts. The main goal of the center is to offer high-quality training to healthcare professionals through 4 complementary curricula in order to ensure maximum satisfaction of their patients.
Ipsen exceeds its targets, helped by its Botox competitor - 11/02/2023
- Family-owned laboratory controlled by descendants of Henri Beaufour
- Ipsen exceeds its targets
- Strong growth in sales of Dysport, its botulinum toxin competitor to Botox, generating €594 million in sales
Ipsen bets $1 billion on a biotech to treat liver disease - 21/01/2023
- Ipsen announces largest acquisition since the sale of Smecta (its family healthcare division) in 2022
- french pharmaceutical group to launch $952 million takeover bid for US biotech Albireo
- By 2021, Ipsen has added 16 new molecules to its portfolio
Ipsen strengthens its position in the dynamic rare diseases segment - 09/01/2023
- Ipsen to pay €1 billion for US biotech Albireo
- The market for rare diseases is close to $150 billion
Companies quoted in this study
This study contains a complete overview of the companies in the market, with the latest figures and news for each company. :
Choosing this study means :
Access to more than 35 hours of work
Our studies are the result of over 35 hours of research and analysis. Using our studies allows you to devote more time and added value to your projects.
Benefit from 6 years' experience and over 1,500 industry reports already produced
Our expertise enables us to produce comprehensive studies in all sectors, including niche and emerging markets.
Our know-how and methodology enable us to produce reports that offer unique value for money.
Access to several thousand articles and paid-for data
Businesscoot has access to all the paid economic press as well as exclusive databases to carry out its market research (over 30,000 articles and private sources).
To enhance our research, our analysts also use web indicators (semrush, trends, etc.) to identify market trends and company strategies. (Consult our paying sources)
Guaranteed support after your purchase
A team dedicated to after-sales service, to guarantee you a high level of satisfaction. +44 238 097 0676
A digital format designed for our users
Not only do you have access to a PDF, but also to a digital version designed for our customers. This version gives you access to sources, data in Excel format and graphics. The content of the study can therefore be easily retrieved and adapted for your specific needs.
Our offers :
the aesthetic medicine market | United Kingdom
- What are the figures on the size and growth of the market?
- What is driving the growth of the market and its evolution?
- What is the positioning of companies in the value chain?
- Data from several dozen databases
5 reports pack (-15%) UK United Kingdom
- 5 reports at €75.6 excluding VAT per study to choose from our UK catalogue for 12 months
- Save 15% on additional studies purchased
- Choose to be refunded any unused credit at the end of the 12-month period (duration of the pack)
See the terms and conditions of the pack and the refund of unused credit.
Our customer references
They have consulted our studies
Discover the opinions (+500)
Malcolm Vincent
Astoria Finance
Gregoire de Castelnau
Stags Participations
Timothé Huignard
PWC
Paul-Alexis Kebabtchieff
BCG
Aymeric Granet
Publicis Consultant
interviews & case studies
All interviews and case studies (45)
